Results 21 to 30 of about 644,115 (313)

Factor Xa Inhibitor

Japanese Journal of Thrombosis and Hemostasis, 2003
Takashi Koizumi, Masahiko Uchida
openalex   +4 more sources

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +1 more source

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Circulation, 2023
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b ...
T. Milling, S. Middeldorp, Lizhen Xu, Bruce R Koch, A. Demchuk, J. Eikelboom, P. Verhamme, A. Cohen, J. Beyer-Westendorf, C. Michael Gibson, J. López-Sendón, M. Crowther, A. Shoamanesh, M. Coppens, Jeannot Schmidt, P. Albaladéjo, S. Connolly, R. Anand, A. Bastani, C. Clark, M. Concha, J. Cornell, K. Dombrowski, G. Fermann, J. Fulmer, J. Goldstein, D. Kereiakes, T. Milling, D. Pallin, N. Patel, M. Refaai, M. Rehman, A. Schmaier, E. Schwarz, W. Shillinglaw, M. Spohn, T. Takata, A. Venkat, J. Welker, I. Welsby, J. Wilson, L. Van Keer, F. Verschuren, M. Blostein, J. Eikelboom, K. Althaus, J. Berrouschot, G. Braun, T. Doeppner, R. Dziewas, S. Genth‐Zotz, P. Greinacher, F. Hamann, F. Hanses, W. Heide, B. Kallmuenzer, P. Kermer, S. Poli, G. Royl, S. Schellong, S. Schnupp, J. Schwarze, C. Spies, G. Thomalla, M. von Mering, K. Weissenborn, F. Wollenweber, C. Gumbinger, U. Jaschinski, M. Maschke, H. Mochmann, W. Pfeilschifter, C. Pohlmann, R. Zahn, P. Bouzat, J. Schmidt, C. Vallejo, B. Floccard, M. Coppens, S. V. van Wissen, E. Arellano-Rodrigo, E. Vallès, R. Alikhan, K. Breen, R. Hall, M. Crowther, P. Albaladéjo, A. Cohen, A. Demchuk, D. Wyse, D. A. Garcia, M. Prins, J. Nakamya, H. Büller, K. Mahaffey, J. Alexander, J. Cairns, R. Hart, C. Joyner, G. Raskob, S. Schulman, R. Veltkamp, B. Meeks, E. Zotova, Sahar Ahmad, T. Pinto, K. Baker, A. Dykstra, I. Holadyk-Gris, Antonio Malvaso   +109 more
semanticscholar   +1 more source

Prediction of inhibition constants of (R)-3-amidinophenylalanine inhibitors toward factor Xa by 2D-QSAR model

Vietnam Journal of Science, Technology and Engineering, 2022
A coagulation cascade forms through proteolytic reactions and involves different factors. There are two coagulation pathways, including intrinsic and extrinsic mechanisms, which converge by the formation of factor Xa.
Thi Bich Van Pham, Minh Hao Hoang
doaj   +1 more source

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa

International Journal of Laboratory Hematology, 2021
Andexanet alfa (AnXa) was developed for anticoagulant effect reversal of direct factor Xa inhibitors (DXaI) (apixaban, rivaroxaban, edoxaban) in emergency situations.
Matthieu Bourdin, Delphine Perrotin, O. Mathieu, Tristan Hervé, F. Depasse, Genmin Lu, P. Conley, G. Contant   +7 more
semanticscholar   +1 more source

Anticoagulation by factor Xa inhibitors [PDF]

Journal of Thrombosis and Haemostasis, 2010
Therapeutic agents that regulate blood coagulation are critical to the management of thrombotic disorders, with the selective targeting of factor (F) Xa emerging as a promising approach.To assess anticoagulant strategies targeting FXa.A deterministic computational model of tissue factor (Tf)-initiated thrombin generation and two empirical experimental ...
Thomas Orfeo, Kathleen E. Brummel-Ziedins, Matthew Gissel, Kenneth G. Mann, Saulius Butenas   +4 more
openaire   +3 more sources

Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile [PDF]

, 2016
Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Afosa, Daniel K., Al-Horani, Rami A., Desai, Umesh R., Karuturi, Rajesh, Lee, Michael   +4 more
core   +7 more sources

Study Of Phenothiazine On p53 Core Domain Mutant Y220C: Finding The Anti-tumor Activity Of Phenothiazine [PDF]

, 2011
The tumor suppressor protein p53 is a transcription factor that plays a key role in the prevention of cancer development. The p53 cancer mutation Y220C induces formation of a cavity on the protein's surface that can accommodate stabilizing small ...
Asif Husain Naqvi, Hardik H. Sheth, Suchindran H S, Vijay Kumar, Vivek Gupta   +4 more
core   +2 more sources

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

Research and Practice in Thrombosis and Haemostasis, 2021
Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák, Hanke M. G. Wiegers, Luuk J. J. Scheres, Barbara A. Hutten, Maria E. deLange, Anne Timmermans, Peter E. Westerweel, Marten R. Nijziel, Marieke J. H. A. Kruip, Marije ten Wolde, Paula F. Ypma, Frederikus A. Klok, Laurens Nieuwenhuizen, Sanne vanWissen, Marcel M. C. Hovens, Laura M. Faber, Pieter W. Kamphuisen, Harry R. Büller, Saskia Middeldorp   +18 more
doaj   +1 more source

Managing patients taking novel oral anticoagulants (NOAs) in dentistry: A discussion paper on clinical implications [PDF]

, 2016
Background The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors ...
Costantinides, Fulvia, Maglione, Michele, Pascazio, Lorenzo, Rizzo, Roberto   +3 more
core   +1 more source